Who are Allegra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zyrtec, Claritin, Xarlin (Levocetirizine), Zyrtec® (cetirizine), Cetirizine tablets, azelastine hydrochloride 0.05%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fexofenadine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Allegra — Competitive Intelligence Brief

Allegra (fexofenadine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Second-generation antihistamine. Area: Metabolic.

marketed Second-generation antihistamine Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Allegra (fexofenadine) — Generic (originally Hoechst Marion Roussel/Sanofi).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Allegra TARGET	fexofenadine	Generic (originally Hoechst Marion Roussel/Sanofi)	marketed	Second-generation antihistamine	Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor	1996-07-25
Zyrtec	cetirizine	Generic (originally UCB Pharma)	marketed	Second-generation antihistamine	Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2	1995-09-29
Claritin	loratadine	Generic (originally Schering-Plough)	marketed	Second-generation antihistamine	Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1	1993-04-12
Xarlin (Levocetirizine)	Xarlin (Levocetirizine)	HK inno.N Corporation	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor
Zyrtec® (cetirizine)	Zyrtec® (cetirizine)	Organon and Co	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor
Cetirizine tablets	Cetirizine tablets	UCB Pharma	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor
azelastine hydrochloride 0.05%	azelastine hydrochloride 0.05%	Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Second-generation antihistamine class)

Generic (originally Hoechst Marion Roussel/Sanofi) · 1 drug in this class
Generic (originally Schering-Plough) · 1 drug in this class
Generic (originally UCB Pharma) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Allegra — Competitive Intelligence Brief. https://druglandscape.com/ci/fexofenadine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab